Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA-CD19 nanobody-based compound CAR-T
- Development stage
- Unknown
- Lead developer
- iCell Gene Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BCMA-CD19 nanobody-based compound CAR-T (ncCAR) is an investigational dual-targeting chimeric antigen receptor (CAR) T-cell therapy developed by iCell Gene Therapeutics. Unlike conventional CAR-T therapies that utilize murine-derived single-chain fragment variables (scFv), this platform employs camelid-derived nanobodies (VHH) to target both B-cell maturation antigen (BCMA) and CD19. This dual-antigen approach is designed to eliminate both CD19+ B cells and BCMA+ long-lived plasma cells, which are considered the root cause of autoantibody production in many autoimmune diseases. The therapy is manufactured using the proprietary Neo-G process, which is designed to shorten manufacturing time by 3-4 days and enhance efficacy. It is currently being evaluated in Phase I clinical trials for systemic lupus erythematosus (SLE) and has demonstrated clinical activity in multiple myeloma and immune thrombocytopenia (ITP).
- Other names
- BCMA-CD19 nanobody-based compound CAR-T cell therapyBCMA-CD-19 nanobody-based compound CAR-T cell therapyBCMA-CD 19 nanobody-based compound CAR-T cell therapy
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on BCMA-CD19 nanobody-based compound CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA-CD19 nanobody-based compound CAR-T.